Complement Activation Profiles Predict Clinical Outcomes in Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease.

MLA

Villacieros-Álvarez, Javier, et al. “Complement Activation Profiles Predict Clinical Outcomes in Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease.” Neurology(R) Neuroimmunology & Neuroinflammation, vol. 12, no. 1, Jan. 2025, p. e200340. EBSCOhost, https://doi.org/10.1212/NXI.0000000000200340.

APA

Villacieros-Álvarez, J., Lunemann, J. D., Sepulveda, M., Valls-Carbó, A., Dinoto, A., Fernández, V., Vilaseca, A., Castillo, M., Arrambide, G., Bollo, L., Espejo, C., Llufriu, S., Blanco, Y., Armangue, T., Álvarez Bravo, G., Quiroga-Varela, A., Ramió Torrentà, L., Cobo-Calvo, A., Tintore, M., … Comabella, M. (2025). Complement Activation Profiles Predict Clinical Outcomes in Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease. Neurology(R) Neuroimmunology & Neuroinflammation, 12(1), e200340. https://doi.org/10.1212/NXI.0000000000200340

Chicago

Villacieros-Álvarez, Javier, Jan D Lunemann, Maria Sepulveda, Adrián Valls-Carbó, Alessandro Dinoto, Victoria Fernández, Andreu Vilaseca, et al. 2025. “Complement Activation Profiles Predict Clinical Outcomes in Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease.” Neurology(R) Neuroimmunology & Neuroinflammation 12 (1): e200340. doi:10.1212/NXI.0000000000200340.